Skip to main content

Market Overview

Why OncoCyte Shares Are Trading Higher Today

Share:
Why OncoCyte Shares Are Trading Higher Today

OncoCyte Corp (NYSE: OCX) shares are advancing to their highest level since the middle of 2019 on above-average volume.

Oncocyte said it has entered into definitive agreements with its two largest institutional investors, namely Pura Vida Investments and Broadwood Partners, to purchase about $25 million of its common shares in a registered offering priced at $3.424 per share.

Subsequent to the offering, ownership interest of Pura Vida will increase from under 10% to about 16%, by virtue of its agreement to buy $20 million worth of shares.

"We believe our strengthened balance sheet will help facilitate our planned expansion activities and offerings in lung and other cancers as we prepare to launch DetermaIO™ and DetermaTX™ later this year, as well as provide the resourcing necessary to complete development of our anticipated blood-based monitoring offerings," said Ron Andrews, CEO of Oncocyte.

At last check, OncoCyte shares were rallying 15.66% to $4.76.

 

Related Articles (OCX)

View Comments and Join the Discussion!

Posted-In: why it's movingNews Penny Stocks Offerings Small Cap Movers Trading Ideas

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com